^
    Back
    Association details:
    Biomarker:SOCS1 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

    Published date:
    02/17/2022
    Excerpt:
    The concomitant presence of mutated SOCS1 with wild-type CREBBP and EP300 defined a group of patients with a favorable prognosis and 2-year progression-free survival (PFS) of 100%.
    DOI:
    10.3390/cancers14041018
    Trial ID:
    SAKK 38/07
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2021
    Title:

    018 | INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY

    Published date:
    06/09/2021
    Excerpt:
    ...141 DLBCL patients received R-CHOP14 immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone every 2 weeks)….The presence of mutations of SOCS1, without mutations in CREBBP and EP300, defined a group of patients with favorable prognosis with a 5-year progression-free survival (PFS) rate of 100%, while patients harboring mutations in CREBBP or EP300 or with SOCS1 wild-type had a 5-year PFS of 69% (p = 0.025).